Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Eliminating Opioid Related Infectious Diseases Act of 2018
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act.
Eliminating Opioid Related Infectious Diseases Act of 2018
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2019 · first_quarter · Q1
Administration drug pricing proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV and oncology products. Medicaid duplicate discounts. Proposed changes to Medicare Part D's six protected classes.
Source: Senate LDA
Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C. International trade and protection of intellectual property. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements.
SUPPORT for Patients and Communities Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act.
Eliminating Opioid Related Infectious Diseases Act of 2018
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act.
Eliminating Opioid Related Infectious Diseases Act of 2018
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C. International trade and protection of intellectual property. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements.
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HR.1628 American Health Care Act and S._ Better Care Reconciliation Act. HR.2212 and S.974 CREATES Act of 2017. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. HR.2430 and S.934 FDA Reauthorization Act; funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
Coverage of pharmaceuticals, cost-sharing and other access issues. HR.2212 and S.974, CREATES Act of 2017. HR. 2430 and S. 934, FDA Reauthorization Act. HR. 1628 American Health Care Act and S. _ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Ryan White Care Act reauthorization; Hepatitis C policy; HIV/AIDS research, testing and treatment. HR. 1628 American Health Care Act of 2017 and S._ Better Care Reconciliation Act; HCV testing, screening and linkage to care programs. HR. 2430 and S. 934, FDA Reauthorization Act. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Coverage of pharmaceuticals, cost-sharing and other access issues. HR.2212 and S.974, CREATES Act of 2017. HR. 2430 and S. 934, FDA Reauthorization Act. HR. 1628 American Health Care Act and S. _ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HR.1628 American Health Care Act and S._ Better Care Reconciliation Act. HR.2212 and S.974 CREATES Act of 2017. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. HR.2430 and S.934 FDA Reauthorization Act; funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
Ryan White Care Act reauthorization; Hepatitis C policy; HIV/AIDS research, testing and treatment. HR. 1628 American Health Care Act of 2017 and S._ Better Care Reconciliation Act; HCV testing, screening and linkage to care programs. HR. 2430 and S. 934, FDA Reauthorization Act. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Coverage of pharmaceuticals, cost-sharing and other access issues. HR.2212 and S.974, CREATES Act of 2017. HR. 2430 and S. 934, FDA Reauthorization Act. HR. 1628 American Health Care Act and S. _ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HR.1628 American Health Care Act and S._ Better Care Reconciliation Act. HR.2212 and S.974 CREATES Act of 2017. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. HR.2430 and S.934 FDA Reauthorization Act; funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HR.1628 American Health Care Act and S._ Better Care Reconciliation Act. HR.2212 and S.974 CREATES Act of 2017. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. HR.2430 and S.934 FDA Reauthorization Act; funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
Coverage of pharmaceuticals, cost-sharing and other access issues. HR.2212 and S.974, CREATES Act of 2017. HR. 2430 and S. 934, FDA Reauthorization Act. HR. 1628 American Health Care Act and S. _ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Ryan White Care Act reauthorization; Hepatitis C policy; HIV/AIDS research, testing and treatment. HR. 1628 American Health Care Act of 2017 and S._ Better Care Reconciliation Act; HCV testing, screening and linkage to care programs. HR. 2430 and S. 934, FDA Reauthorization Act. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HR.1628 American Health Care Act and S._ Better Care Reconciliation Act. HR.2212 and S.974 CREATES Act of 2017. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. HR.2430 and S.934 FDA Reauthorization Act; funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Coverage of pharmaceuticals, cost-sharing and other access issues. HR.2212 and S.974, CREATES Act of 2017. HR. 2430 and S. 934, FDA Reauthorization Act. HR. 1628 American Health Care Act and S. _ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2018 · fourth_quarter · Q4
Administration drug pricing proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.
Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicaid duplicate discounts.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2018 · third_quarter · Q3
Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act.
Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs". HCV testing, screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicaid duplicate discounts.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2018 · first_quarter · Q1
Technology transfer, patent rights and funding, patent reform legislation. Issues related to pharmaceuticals and intellectual property protection.
Implementation of the Tax Cuts and Jobs Act of 2017 (P.L. 115-97)
HCV testing, screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals. Medicaid duplicate discounts.
International trade and protection of intellectual property; compulsory licensing issues in multiple countries.
Issues related to pharmaceuticals and international finance for health services. Access to medicines and intellectual property protection.
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program.
Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C. International trade and protection of intellectual property. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2017 · fourth_quarter · Q4
Technology transfer, patent rights and funding, patent reform legislation. Issues related to pharmaceuticals and intellectual property protection.
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C. International trade and protection of intellectual property.
HCV testing, screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals. Medicaid duplicate discounts.
Issues related to pharmaceuticals and international finance for health services. Access to medicines and intellectual property protection.
Tax Cuts and Jobs Act of 2017 (P.L. 115-97)
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program.
International trade and protection of intellectual property
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2017 · third_quarter · Q3
Issues related to pharmaceuticals and international finance for health services. Access to medicines and intellectual property protection.
Issues related to international and corporate tax reform. The House Republican Tax Reform Blueprint, President Trump's Tax Reform Principles, the Senate's tax reform efforts, and the Joint Statement on Tax Reform.
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio.Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2017 · second_quarter · Q2
International trade and protection of intellectual property
Education related to HIV and Hepatitis C in American Indian population.
Issues related to international and corporate tax reform
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2017 · first_quarter · Q1
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio; funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
Education related to Hepatitis C in prison population.
Ryan White Care Act reauthorization; Hepatitis C policy; HIV/AIDS research, testing and treatment. HCV testing, screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals.
Education related to Hepatitis C in American Indian population.
Coverage of pharmaceuticals, cost-sharing and other access issues. Issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program.
International trade and protection of intellectual property
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA)
Issues related to pharmaceuticals and international finance for health services. Intellectual property protection.
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HR.1628 American Health Care Act and S._ Better Care Reconciliation Act. HR.2212 and S.974 CREATES Act of 2017. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. HR.2430 and S.934 FDA Reauthorization Act; funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.
Coverage of pharmaceuticals, cost-sharing and other access issues. HR.2212 and S.974, CREATES Act of 2017. HR. 2430 and S. 934, FDA Reauthorization Act. HR. 1628 American Health Care Act and S. _ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program.
Ryan White Care Act reauthorization; Hepatitis C policy; HIV/AIDS research, testing and treatment. HR. 1628 American Health Care Act of 2017 and S._ Better Care Reconciliation Act; HCV testing, screening and linkage to care programs. HR. 2430 and S. 934, FDA Reauthorization Act. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA)
International trade and protection of intellectual property
Education related to Hepatitis C in American Indian population.
Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; HIV/AIDS research, testing and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Education related to Hepatitis C
Issues related to international and corporate tax reform
Issues related to healthcare funding and cost-savings.
Technology transfer, patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to pharmaceuticals and intellectual property protection. Intellectual property reform.
Coverage of pharmaceuticals, cost-sharing and other access issues; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and Affordable Care Act implementation; FDA issues and 340B.
Issues related to pharmaceuticals, international finance for health services and intellectual property protection.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)